Research misconduct GCP rules cover more ground than the academic misconduct standard researchers may already know. Under FDA bioresearch-monitoring (BIMO) authority and Good Clinical Practice, misconduct in a clinical trial can include protocol violations, unprotected human subjects and data-integrity failures — not only fabrication, falsification or plagiarism. This creates a parallel compliance track that runs alongside, and sometimes collides with, the Office of Research Integrity’s (ORI) Public Health Service (PHS) misconduct policy.
Research misconduct, under 42 CFR Part 93, is defined by ORI as “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results” — committed intentionally, knowingly, or recklessly, and representing a significant departure from accepted practice. GCP misconduct, by contrast, is judged against compliance with the trial protocol, informed-consent rules and data-integrity requirements set out in FDA regulations, and does not hinge on the same intent test.
- What counts as research misconduct under FDA and GCP rules?
- How does ORI/PHS academic policy differ?
- What triggers an FDA bioresearch-monitoring investigation?
- What happens when a trial falls under both frameworks?
- Frequently asked questions
What Counts as Research Misconduct Under FDA and GCP Rules?
FDA’s Bioresearch Monitoring programme inspects clinical investigators, sponsors, monitors and institutional review boards for compliance with clinical trial regulations, principally 21 CFR Parts 50, 56 and 312 and the internationally harmonised ICH E6(R2) Good Clinical Practice guideline. Misconduct in this context extends well beyond fabrication, falsification and plagiarism (FFP).
It can include failing to protect human subjects, proceeding without valid informed consent, deviating repeatedly from the approved protocol, or under-reporting adverse events. FDA inspectors have described a lower practical bar for sanction than the PHS intent standard: repeated or negligent noncompliance with GCP can itself justify action, even without proof of deliberate deception.
How Does ORI/PHS Academic Misconduct Policy Differ?
ORI oversees institutions receiving PHS funding — chiefly NIH grants — under the narrower FFP definition. A finding requires evidence of intent (“intentionally, knowingly, or recklessly”) and a significant departure from accepted research practice. Honest error and genuine differences of scientific opinion are explicitly excluded.
The table below sets out the core distinctions between the two frameworks.
| Dimension | ORI/PHS academic policy | FDA GCP/BIMO framework |
|---|---|---|
| Core definition | Fabrication, falsification, plagiarism (FFP) | FFP plus GCP deviations: consent failures, protocol breaches, data-integrity gaps |
| Governing rule | 42 CFR Part 93 | 21 CFR Parts 50, 56, 312; ICH E6(R2) |
| Intent threshold | Intentional, knowing or reckless; “significant departure” | Can extend to negligent or repeated noncompliance |
| Jurisdiction | PHS-funded research only | Any trial data submitted to FDA in a marketing application, funded or not |
| Investigator | Institutional integrity officer, ORI oversight | FDA Office of Scientific Investigations / BIMO inspectors |
| Typical sanction | Federal funding debarment, supervision, record correction | Clinical investigator disqualification (21 CFR 312.70), data rejection, debarment |
The practical consequence: a fully compliant academic institution can still have a GCP problem, and a well-run industry trial with no PHS funding at all is entirely outside ORI’s remit but squarely inside FDA’s.
What Triggers an FDA Bioresearch-Monitoring Investigation?
BIMO inspections are risk-based and routine as well as complaint-driven. FDA selects clinical investigator sites for inspection using data anomalies, unusually favourable results, high enrolment rates, complaints, or as a standard check ahead of marketing-application review.
- Falsified or fabricated case-report-form data submitted in an IND or NDA;
- Repeated protocol deviations affecting subject safety or data validity;
- Informed-consent documentation failures under 21 CFR Part 50;
- Institutional review board oversight lapses under 21 CFR Part 56;
- Undisclosed financial conflicts of interest affecting trial conduct.
Confirmed findings can lead to disqualification of a clinical investigator under 21 CFR 312.70, rejection of the affected data from a submission, referral for criminal prosecution, or debarment under the Federal Food, Drug, and Cosmetic Act’s Application Integrity Policy.
What Happens When a Trial Falls Under Both Frameworks?
Many clinical trials are simultaneously NIH-funded (triggering PHS/ORI jurisdiction) and submitted to FDA in support of an IND or marketing application (triggering GCP/BIMO jurisdiction). In that scenario, a single allegation can spawn two parallel investigations, run by different bodies, applying different definitions, evidentiary thresholds and remedies.
ORI’s process centres on correcting the scientific record and imposing funding-related sanctions on the individual researcher. FDA’s process centres on protecting trial subjects and the integrity of data submitted for regulatory approval, and can act against a sponsor, monitor or institution as well as an investigator. Research administrators managing multi-funded trials need policies that map obligations under both tracks, since satisfying one does not discharge the other.
For institutions, the practical implication is a dual-reporting duty: allegations touching FDA-regulated data may need parallel notification to the institution’s research integrity officer and, where applicable, to the FDA sponsor or IND holder — a distinction general research-misconduct training rarely covers.
Frequently Asked Questions
What are the three types of research misconduct?
Under ORI/PHS policy, the three recognised types are fabrication (making up data), falsification (manipulating materials or omitting results) and plagiarism (using others’ work without credit) — collectively known as FFP. FDA/GCP rules recognise these plus separate categories tied to human-subject protection and protocol compliance.
What counts as research misconduct?
Research misconduct is conduct that deliberately or recklessly falls short of accepted research standards, spanning proposal, conduct and reporting. Under GCP, it also covers protocol deviations, invalid consent and unreported adverse events — behaviours the narrower academic FFP definition does not automatically capture.
What are some examples of research misconduct?
Examples include fabricating patient outcomes, falsifying case-report-form entries, plagiarising a manuscript, enrolling subjects without valid informed consent, and concealing a serious adverse event from a sponsor or IRB. The last three are GCP-specific failures with no direct ORI/PHS equivalent.
What are the 5 unethical practices in research?
Commonly cited categories are falsification of data, failure to credit others, plagiarism, undisclosed conflicts of interest, and biased design or interpretation. In FDA-regulated trials, a sixth practical category applies: noncompliance with GCP itself, regardless of intent.
As FDA-regulated trials grow more complex and more federally co-funded research crosses into the BIMO’s remit, institutions running clinical research increasingly need compliance frameworks built to satisfy both standards concurrently, rather than treating GCP obligations as an addendum to existing academic misconduct policy. Building that dual-track literacy into institutional training is the clearest way to close the gap this comparison exposes.
For related institutional context, see CASRAI’s overview of research administration compliance frameworks and the research integrity dictionary for definitions of adjacent terms.
Leave a Reply